nach oben

Erschienen in:

01.04.2009 | Review Article

Endometriosis

Current Therapies and New Pharmacological Developments

verfasst von: Prof. Paolo Vercellini, Edgardo Somigliana, Paola Viganò, Annalisa Abbiati, Giussy Barbara, Pier Giorgio Crosignani

Erschienen in: Drugs | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Endometriosis is a chronic inflammatory condition that is responsive to management with steroids. The establishment of a steady hormonal environment and inhibition of ovulation can temporarily suppress ectopic implants and reduce inflammation as well as associated pain symptoms. In terms of pharmacological management, the currently available agents are not curative, and treatment often needs to be continued for years or until pregnancy is desired. Similar efficacy has been observed from the various therapies that have been investigated for endometriosis. Accordingly, combined oral contraceptives and progestins, based on their favourable safety profile, tolerability and cost, should be considered as first-line options, as an alternative to surgery and for post-operative adjuvant use. In situations where progestins and oral contraceptives prove ineffective, are poorly tolerated or are contraindicated, gonadotrophin-releasing hormone analogues, danazol or gestrinone may be used. Future therapeutic options for managing endometriosis must compare favourably against existing agents before they can be considered for inclusion into current practice. Finally, as reproductive prognosis is not ameliorated by medical treatment, it is not indicated for women seeking conception.

Vercellini P, Fedele L, Aimi G, et al. Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: the predictive value of the current system. Hum Reprod 2006; 21: 2679–85PubMedCrossRef

Vercellini P, Fedele L, Pietropaolo G, et al. Progestogens for endometriosis: forward to the past. Hum Reprod Up 2003; 9: 387–96CrossRef

The American College of Obstetricians and Gynecologists. Medical management of endometriosis: number 11, December 1999. Int J Gynaecol Obstet 2000; 71: 183–96CrossRef

Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril 2006; 86: S156–60

Kennedy S, Bergqvist A, Chapron C, et al. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698–704

Telimaa S, Puolakka J, Ronnberg L, et al. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol 1987; 1: 13–23PubMedCrossRef

Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate) for depot suspension in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril 1990; 54: 419–27PubMed

Fedele L, Bianche S, Bocciolone L, et al. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Steril 1993; 59: 516–21PubMed

Bergqvist A, Bergh T, Hogstöm L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril 1998; 69: 702–8PubMedCrossRef

10.

Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol 2008; 22: 275–306PubMedCrossRef

11.

Prentice A. Endometriosis. BMJ 2001; 323: 93–5PubMedCrossRef

12.

Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68: 393–401PubMedCrossRef

13.

Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60: 75–9PubMed

14.

Parazzini F, Di Cintio E, Chatenoud L, et al. Estroprogestin vs. gonadotropin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Eur J Obstet Gynecol Reprod Biol 2000; 88: 11–4

15.

Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90: 1583–8PubMedCrossRef

16.

Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179–83PubMedCrossRef

17.

Sulak P, Thomas J, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142–9PubMedCrossRef

18.

Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75: 444–9PubMedCrossRef

19.

Duleba AJ, Keltz MD, Olive DL. Evaluation and management of chronic pelvic pain. J Am Assoc Gynecl Laparosc 1996; 3: 205–27CrossRef

20.

Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80: 560–3PubMedCrossRef

21.

Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med 1998; 43: 24–7PubMed

22.

Moore C, Kohler G, Muller A. The treatment of endometriosis with dienogest. Drugs Today 1999; 35 Suppl. C: 41–52

23.

Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs: a review. Am J Obstet Gynecol 2002; 187: 1101–6PubMedCrossRef

24.

Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007; 92: 2205–7PubMedCrossRef

25.

Beksinska ME, Kleinschmidt I, Smit JA, et al. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. Contraception 2007; 75: 438–43PubMedCrossRef

26.

Beksinska ME, Smit JA, Kleinschmidt I, et al. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception 2005; 71: 170–5PubMedCrossRef

27.

Fedele L, Arcaini L, Bianchi S, et al. Comparison of cyproterone acetate and danazol in the treatment of pelvic pain associated with endometriosis. Obstet Gynecol 1989; 73: 1000–4PubMedCrossRef

28.

Moran C, Alcivia JC, Garcia-Hernandez E, et al. Treatment of endometriosis with cyproterone acetate: preliminary report. Arch Med Res 1996; 27: 535–8PubMed

29.

Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002; 77: 52–61PubMedCrossRef

30.

Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000; 74: 24–30PubMedCrossRef

31.

The American Fertility Society. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 1985; 43: 351–2

32.

Bergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand 2001; 80: 628–37PubMedCrossRef

33.

Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994; 170: 1543–9PubMed

34.

Skegg DCG, Noonan EA, Paul C, et al. Depot medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand Studies. JAMA 1995; 273: 799–804PubMedCrossRef

35.

Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991; 303: 13–6PubMedCrossRef

36.

Scholes D, LaCroix AZ, Ichikawa LE, et al. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002; 13: 581–7PubMedCrossRef

37.

Clark MK, Sowers MR, Nichols S, et al. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82: 1580–6PubMedCrossRef

38.

Shaarawy M, El-Mallah SY, Seoudi S, et al. Effect of long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception 2006; 74: 297–302PubMedCrossRef

39.

Cundy T, Cornish J, Roberts H, et al. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 2002; 186: 978–83PubMedCrossRef

40.

Cundy T, Cornish J, Evans MC, et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 1994; 308: 247–8PubMedCrossRef

41.

Orr-Walker BJ, Evans MC, Ames RW, et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 1998; 49: 615–8CrossRef

42.

Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21: 248–56PubMedCrossRef

43.

Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175: 396–401PubMedCrossRef

44.

Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosisassociated pain. Fertil Steril 2006; 85: 314–25PubMedCrossRef

45.

Salmi A, Pakarinen P, Peltola AM, et al. The effect of intrauterine levonorgestrel use on the expression of C-Jun, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol Hum Reprod 1998; 4: 1110–5PubMedCrossRef

46.

Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod 2004; 19: 179–84PubMedCrossRef

47.

Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734–9PubMedCrossRef

48.

Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005; 20: 789–93PubMedCrossRef

49.

Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20: 1993–8PubMedCrossRef

50.

Vercellini P, Aimi G, Panazza S, et al. A levonorgestrelreleasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999; 72: 505–8PubMedCrossRef

51.

Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003; 80: 305–9PubMedCrossRef

52.

Shulman LP, Nelson AL, Darney PD. Recent developments in hormone delivery system. Am J Obstet Gynecol 2004; 190: S39–48PubMedCrossRef

53.

Jain S, Dalton ME. Chocolate cysts from ovarian follicles. Fertil Steril 1999; 72: 852–6PubMedCrossRef

54.

Vercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol 2005; 17: 359–65PubMedCrossRef

55.

Ewies AAA. Mirena: the other side of the story. BJOG 2007; 114: 1307–8PubMedCrossRef

56.

Fedele L, Bianchi S, Zanconato G, et al. Long-term follow-up after conservative surgery for rectovaginal endometriosis. Am J Obstet Gynecol 2004; 190: 1020–4PubMedCrossRef

57.

Ford J, English J, Miles WA, et al. Pain, quality of life and complications following the radical resection of rectovaginal endometriosis. BJOG 2004; 111: 353–6PubMedCrossRef

58.

Vercellini P, Frontino G, Pietropaolo G, et al. Deep endometriosis: definition, pathogenesis, and clinical management. J Am Assoc Gynecol Laparosc 2004; 11: 127–36CrossRef

59.

Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485–8PubMedCrossRef

60.

Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005; 84: 1375–87PubMedCrossRef

61.

Remorgida V, Abbamonte HL. Letrozole and norethisterone acetate in rectovaginal endometriosis. Fertil Steril 2007; 88: 724–6PubMedCrossRef

62.

Kikuchi I, Takeuchi H, Shimanuki H, et al. Recurrence rate of endometriomas following laparoscopic cystectomy. Acta Obstet Gynecol Scand 2006; 85: 1120–4PubMedCrossRef

63.

Koga K, Takemura Y, Osuga Y, et al. Recurrence of ovarian endometrioma after laparoscopic excision. Hum Reprod 2006; 21: 2171–4PubMedCrossRef

64.

Liu X, Yuan L, Shen F, et al. Patterns of and risk factors for recurrence in women with ovarian endometriomas. Am J Obstet Gynecol 2007; 109: 1411–20CrossRef

65.

Busacca M, Chiaffarino F, Candiani M, et al. Determinants of long term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol 2006; 195: 426–32PubMedCrossRef

66.

Vercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008; 198: 504e1-5PubMedCrossRef

67.

Missmer SA, Hankinson SE, Spiegelman D, et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 2004; 104: 965–74PubMedCrossRef

68.

Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 2003; 189: 280–94PubMedCrossRef

69.

Vigano P, Somigliana E, Chiodo I, et al. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update 2006; 12: 77–89PubMedCrossRef

70.

Somigliana E, Vigano P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101: 331–41PubMedCrossRef

71.

Vigano P, Somigliana E, Parazzini F, et al. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril 2007; 88: 588–93PubMedCrossRef

72.

Modugno F, Ness RB, Allen GO, et al. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004; 191: 733–40PubMedCrossRef

73.

Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric 2006; 9: 325–35PubMedCrossRef

74.

Reimnitz C, Brand E, Nieberg RK, et al. Malignancy arising in endometriosis associated with unopposed estrogen replacement. Obstet Gynecol 1988; 71: 444–7PubMed

75.

Lavery S, Gillmer M. Malignant transformation of residual endometriosis in women on unopposed oestrogen hormone replacement therapy. BJOG 2001; 108: 1106–7PubMed

76.

Soliman NF, Evans AJ. Malignancy arising in residual endometriosis following hysterectomy and hormone replacement therapy. J Br Menopause Soc 2004; 10: 123–4PubMed

77.

Gücer F, Pieber D, Arikan MG. Malignancy arising in extraovarian endometriosis during estrogen stimulation. Eur J Gynaecol Oncol 1998; 19: 39–41PubMed

78.

Zanetta GM, Webb MJ, Li H, et al. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol 2000; 79: 18–22PubMedCrossRef

79.

Jones KD, Owen E, Berresford A, et al. Endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon. Gynecol Oncol 2002; 86: 220–2PubMedCrossRef

80.

Oxholm D, Knudsen UB, Kryger-Baggesen N, et al. Postmenopausal endometriosis. Acta Obstet Gynecol Scand 2007; 4: 1–7

81.

Haney AF, Wild RA. Options for hormone therapy in women who have had a hysterectomy. Menopause 2007; 14: 592–7PubMedCrossRef

82.

Fedele L, Bianchi S, Raffaelli R, et al. Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas 1999; 32: 189–93PubMedCrossRef

83.

Lindsay PC, Shaw RW, Bennink HJ, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996; 65: 342–8PubMed

84.

Janssens RM, Brus L, Cahill DJ, et al. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000; 6: 505–18PubMedCrossRef

85.

Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol 2005; 184: 11–28

86.

Huirne JA, Lambalk CB. Gonadotropin-releasinghormone-receptor antagonists. Lancet 2001; 358:1793–803PubMedCrossRef

87.

Olive D. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 2004; 3: 83–9PubMedCrossRef

88.

Batzer FR. GnRH analogs: options for endometriosisassociated pain treatment. J Minim Invasive Gynecol 2006; 13: 539–45PubMedCrossRef

89.

Davis L, Kennedy S, Moore J, et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; 3: CD001019PubMed

90.

Prentice A, Deary A, Goldbeck-Wood S, et al. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2007; 3: CD000346

91.

Pickersgill A. GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynaecol 1998; 105: 475–85PubMedCrossRef

92.

Bedaiwy M, Casper R. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 2006; 86: 220–2PubMedCrossRef

93.

Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993; 59: 511–5PubMed

94.

Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740–5PubMed

95.

Casper R. Estrogen with interrupted progestin HRT: a review of experimental and clinical studies. Maturitas 2000; 34: 97–108PubMedCrossRef

96.

Mitwally MF, Gotlieb L, Casper R. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premestrual syndrome. Menopause 2002; 9: 236–41PubMedCrossRef

97.

Surrey E, Hornstein M. Prolonged GnRH agonist and addback therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99: 709–19PubMedCrossRef

98.

Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82: 1303–8PubMedCrossRef

99.

Schindler AE. Gonadotropin-releasing hormone agonists for prevention of postoperative adhesions: an overview. Gynecol Endocrinol 2004; 19: 51–5PubMedCrossRef

100.

Vercellini P, Frontino G, De Giorgi O, et al. Endometriosis: preoperative and postoperative medical treatment. Obstet Gynecol Clin North Am 2003; 30: 163–80PubMedCrossRef

101.

Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004; 3: CD003678PubMed

102.

Parazzini F, Fedele L, Busacca M, et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 1994; 171: 1205–7PubMed

103.

Hornstein R, Hemmings AA, Yuzpe H. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997; 68: 860–4PubMedCrossRef

104.

Vercellini P, Crosignani PG, Fadini R, et al. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynecol 1999; 106: 672–7CrossRef

105.

Busacca M, Somigliana E, Bianchi S, et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III/IV: a randomized controlled trial. Hum Reprod 2001; 16: 2399–402PubMed

106.

Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002; 77: 684–92PubMedCrossRef

107.

Loverro G, Carriero C, Rossi AC, et al. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 2008 Feb; 136(2): 194–8PubMedCrossRef

108.

Dicker D, Goldman GA, Ashkenazi J, et al. The value of pre-treatment with gonadotrophin releasing hormone (GnRH) analogue in IVF-ET therapy of severe endometriosis. Hum Reprod 1990; 5: 418–20PubMed

109.

Sallam HN, Garcia-Velasco JA, Dias S, et al. Long-term pituitary down regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006; 1: CD004635PubMed

110.

Dicker D, Goldman JA, Levy T, et al. The impact of long-term gonadotropin-releasing hormone analogue treatment on preclinical abortions in patients with severe endometriosis undergoing in vitro fertilization-embryo transfer. Fertil Steril 1992; 57: 597–600PubMed

111.

Rickes D, Nickel I, Kropf S, et al. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertil Steril 2002; 78: 757–62PubMedCrossRef

112.

Surrey ES, Silverberg KM, Surrey MW, et al. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril 2002; 78: 699–704PubMedCrossRef

113.

Somigliana E, Vercellini P, Vigano P, et al. Should endometriomas be treated before IVF-ICSI cycles? Hum Reprod Update 2006; 12: 57–64PubMedCrossRef

114.

Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000; 6: 322–31PubMedCrossRef

115.

Albano C, Platteau P, Devroey P. Gonadotropin-releasing hormone antagonist: how good is the new hope? Curr Opin Obstet Gynecol 2001; 13: 257–62PubMedCrossRef

116.

Felberbaum RE, Kupker W, Diedrich K. Will GnRH antagonists assist in the treatment of benign gynaecological diseases? Reprod Biomed Online 2002; 5 Suppl. 1: 68–72PubMedCrossRef

117.

Armer RE, Smelt KH. Non-peptidic GnRH receptor antagonists. Curr Med Chem 2004; 11: 3017–28PubMedCrossRef

118.

Schultze-Mosgau A, Griesinger G, Altgassen C, et al. New developments in the use of peptide gonadotropinreleasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005; 14: 1085–97PubMedCrossRef

119.

Finas D, Hornung D, Diedrich K, et al. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother 2006; 7: 2155–68PubMedCrossRef

120.

Kupker W, Felberbaum RE, Krapp M, et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002; 5: 12–6PubMedCrossRef

121.

Pabuccu R, Onalan G, Kaya C. GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2007; 88: 832–9PubMedCrossRef

122.

Struthers RS, Xie Q, Sullivan SK, et al. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology 2007; 148: 857–67PubMedCrossRef

123.

Crosignani P, Olive D, Bergqvist A, et al. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006; 12: 179–89PubMedCrossRef

124.

Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial. N Engl J Med 1988; 318: 485–9PubMedCrossRef

125.

Fraser IS, Shearman RP, Jansen RP, et al. A comparative treatment trial of endometriosis using the gonadotrophinreleasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol 1991; 31: 158–63PubMedCrossRef

126.

Rotondi M, Labriola D, Rotondi M, et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol 2002; 23: 523–6PubMed

127.

Selak V, Farquhar C, Prentice A, et al. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001; 4: CD000068PubMed

128.

Bianchi S, Busacca M, Agnoli B, et al. Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study. Hum Reprod 1999; 14: 1335–7PubMedCrossRef

129.

Cobellis L, Razzi S, Fava A, et al. A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dispareunia associated with endometriosis. Fertil Steril 2004; 82: 239–40PubMedCrossRef

130.

Razzi S, Luisi S, Calonaci F, et al. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril 2007; 88: 789–94PubMedCrossRef

131.

Surrey ES. The role of progestins in treating the pain of endometriosis. J Minim Invasive Gynecol 2006; 13: 528–34PubMedCrossRef

132.

Fedele L, Bianchi S, Viezzoli T, et al. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril 1989; 51: 781–5PubMed

133.

Gestrinone Italian Study Group. Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Fertil Steril 1996; 66: 911–9

134.

Seli E, Berkkanoglu M, Arici A. Pathogenesis of endometriosis. Obstet Gynecol Clin N Am 2003; 30: 41–61CrossRef

135.

Lake DE, Hudis C. Aromatase inhibitors in breast cancer: an update. Cancer Control 2002; 9: 490–8PubMed

136.

Bulun SE, Zeitoun KM, Takayama K, et al. Aromatase expression in endometriosis: biology and clinical perspectives. In: Lemay A, Maheux R, editors. Understanding and managing endometriosis: advances in research and practice. Quebec City (QC): Parthenon Publishing, 1998: 139–48

137.

Bulun SE, Zeitoun KM, Takayama K, et al. Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update 2000; 6: 413–8PubMedCrossRef

138.

Miller WR, Anderson TJ, Dixon JM. Anti-tumor effects of letrozole. Cancer Invest 2002; 20: 15–21PubMedCrossRef

139.

Viganò P, Mangioni S, Odorizzi MP, et al. Use of estrogen antagonists and aromatase inhibitors in endometriosis. Curr Opin Investig Drugs 2003 Oct; 4(10): 1209–12PubMed

140.

Vignali M, Infantino M, Matrone R, et al. Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 2002; 78: 665–78PubMedCrossRef

141.

Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004; 81: 290–6PubMedCrossRef

142.

Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005; 84: 300–4PubMedCrossRef

143.

Soysal S, Soysal ME, Ozer S, et al. The effects of postsurgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004; 19: 160–7PubMedCrossRef

144.

Ho HN, Wu MY, Yang YS. Peritoneal cell immunity and endometriosis. Am J Reprod Immunol 1997; 38: 400–12PubMedCrossRef

145.

Sharpe-Timms KL. Basic research in endometriosis. Obstet Gynecol Clin Nor Am 1997; 24: 269–90CrossRef

146.

Kupker W, Schultze-Mosgau A, Diedrich K. Paracrine changes in the peritoneal environment of women with endometriosis. Hum Reprod Update 1998; 4: 719–23PubMedCrossRef

147.

Lebovic DI, Mueller M, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001; 75: 1–10PubMedCrossRef

148.

Biron CA. Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998; 10: 383–90PubMedCrossRef

149.

Goodman MG, Reitz AB, Chen R, et al. Selective modulation of elements of the immune system by low molecular weight nucleosides. J Pharmacol Exp Ther 1995; 274: 1552–7PubMed

150.

Holcombe RF, Milovanovic T, Stewart RM, et al. Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints. Cancer Detect Prev 2001;25: 183–91PubMed

151.

Namazi MR. Levamisole: a safe and economical weapon against pediculosis. Int J Dermatol 2001; 40: 292–3PubMedCrossRef

152.

Ingelmo JM, Quereda F, Acien P. Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a murine model. Fertil Steril 1999; 71: 907–11PubMedCrossRef

153.

Keenan JA, Williams-Boyce PK, Massey PJ, et al. Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril 1999; 72: 135–41PubMedCrossRef

154.

Somigliana E, Vigano P, Rossi G, et al. Endometrial ability to implant in ectopic sites can be prevented by interleukin12 in a murine model of endometriosis. Hum Reprod 1999; 14: 2944–50PubMedCrossRef

155.

Badawy SZ, Etman A, Cuenca V, et al. Effect of interferon alpha-2b on endometrioma cells in vitro. Obstet Gynecol 2001; 98: 417–20PubMedCrossRef

156.

Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001; 76: 223–31PubMedCrossRef

157.

Chishima F, Hayakawa S, Sugita K, et al. Increased expression of cyclooxygenase-2 in local lesions of endometriosis patients. Am J Reprod Immunol 2002; 48: 50–6PubMedCrossRef

158.

Matsuzaki S, Canis M, Pouly JL, et al. Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril 2004; 82: 1309–15PubMedCrossRef

159.

Lev-Ari S, Lichtenberg D, Arber N. Compositions for treatment of cancer and inflammation. Recent Pat Anticancer Drug Discov 2008 Jan; 3(1): 55–62PubMedCrossRef

160.

Efstathiou JA, Sampson DA, Levine Z, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005 Jan; 83(1): 171–81PubMedCrossRef

161.

Hull ML, Prentice A, Wang DY, et al. Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Hum Reprod 2005 Feb; 20(2): 350–8PubMedCrossRef

162.

Cobellis L, Razzi S, De Simone S, et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 116: 100–2PubMedCrossRef

163.

Barrier BF, Bates GW, Leland MM, et al. Efficacy of antitumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 2004; 81 Suppl. 1: 775–9PubMedCrossRef

164.

Koninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008; 23: 2017–23PubMedCrossRef

165.

Healy DL, Rogers PA, Hii L, et al. Angiogenesis: a new theory for endometriosis. Hum Reprod Update 1998; 4: 736–40PubMedCrossRef

166.

McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45–55PubMedCrossRef

167.

Donnez J, Smoes P, Gillerot S, et al. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998; 13: 1686–90PubMedCrossRef

168.

McLaren J, Prentice A, Charnock-Jones DS, et al. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996; 11: 220–3PubMedCrossRef

169.

Tan XJ, Lang JH, Liu DY, et al. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002; 78: 148–53PubMedCrossRef

170.

Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005 Oct; 84 Suppl. 2: 1144–55PubMedCrossRef

171.

Chabbert-Buffet N, Meduri G, Bouchard P, et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005; 11: 293–307PubMedCrossRef

172.

Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005; 26: 423–38PubMedCrossRef

173.

Olive DL, Lindheim SR, Pritts EA. New medical treatments for endometriosis. Best Pract Res Clin Obstet Gynaecol 2004; 18: 319–28PubMedCrossRef

174.

Ferrero S, Abbamonte LH, Anserini P, et al. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv 2005; 60: 817–26PubMedCrossRef

175.

Chwalisz K, Mattia-Goldberg C, Lee M, et al. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) Asoprisnil. Fertil Steril 2004; 82: S83–4CrossRef

176.

Royal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis: guideline no. 24. London: RCOG Press, 2006 Jun

Titel: Endometriosis
Current Therapies and New Pharmacological Developments
verfasst von: Prof. Paolo Vercellini
Edgardo Somigliana
Paola Viganò
Annalisa Abbiati
Giussy Barbara
Pier Giorgio Crosignani
Publikationsdatum: 01.04.2009
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 6/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200969060-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Olmesartan Medoxomil/Amlodipine

Pharmacotherapy for the Secondary Prevention of Stroke

Ferric Carboxymaltose

Medical Expulsive Therapy for Distal Ureteral Stones

Community-Associated Meticillin-Resistant Staphylococcus aureus Infections

Fesoterodine